HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts FibroGen (FGEN) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel
May 08, 2021 13:15 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, May 08, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. Class Period: Oct. 18, 2017 – Apr....
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts FibroGen (FGEN) Investors to Securities Fraud Lawsuit and Application Deadline, Advises Investors with Losses to Contact Its Attorneys Now
May 03, 2021 14:00 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. Class Period: Nov. 8, 2019 – Apr. 6,...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug
April 12, 2021 10:05 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, April 12, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. The firm is investigating possible...